MST1R Antibody, HRP conjugated

RON (MST1R) is a receptor tyrosine kinase that transduces signals from the extracellular matrix to the cytoplasm upon binding to its ligand, MST1. It plays a crucial role in various physiological processes, including cell survival, migration, and differentiation. Ligand binding initiates autophosphorylation of RON's intracellular domain, creating docking sites for downstream signaling molecules. Activated RON interacts with proteins such as the PI3-kinase subunit PIK3R1, PLCG1, and the adapter GAB1, triggering signaling cascades including RAS-ERK, PI3 kinase-AKT, and PLCgamma-PKC. RON signaling is vital in wound healing, promoting epithelial cell migration, proliferation, and survival at the wound site. It also contributes to the innate immune response by regulating macrophage migration and phagocytic activity. Importantly, RON can also mediate cell migration and proliferation in response to growth factors beyond MST1.

Extensive research highlights RON's multifaceted role in various cancers. Studies have investigated:

• The regulation of RON alternative splicing, particularly exon 11, and its implications in oncogenesis. (PMID: 30120239)
• The functional significance of RON in prostate cancer progression and its potential as a therapeutic target to overcome androgen deprivation therapy resistance. (PMID: 30121008)
• The presence of RON splice variants lacking exon 11 and exons 11-13 in lung cancer cell lines, including a potentially secreted truncated isoform. (PMID: 30223007)
• The role of the RONDelta165E2 variant in colorectal carcinoma progression through PI3K/AKT pathway activation via PTEN phosphorylation. (PMID: 28388571)
• The involvement of RON and c-Met in metastasis via ERK1/2 signaling, suggesting their combined targeting as a potential therapeutic strategy in prostate cancer. (PMID: 28440432)
• The regulation of RON by FOXC1 in melanoma, activating the MST1R/PI3K/AKT pathway. (PMID: 27533251)
• RON's contribution to cancer-induced bone destruction and osteoporosis. (PMID: 28123075)
• The prevalence of RON isoforms in pancreatic cancer, and their regulation via promoter hypermethylation. (PMID: 27323855)
• The association of high RON expression with castration-resistant prostate cancer. (PMID: 26872377)
• The regulation of RON mRNA translation by hnRNP A1 through G-quadruplex RNA structures. (PMID: 26930004)
• RON as a potential therapeutic target in pancreatic cancer. (PMID: 26477314)
• The association of high RON expression with drug resistance in bladder cancer. (PMID: 28075465)
• The prognostic significance of MET and RON expression levels in extrahepatic cholangiocarcinoma, particularly regarding lymph node metastasis. (PMID: 27919987)
• The identification of novel RON splice variants in lung cancer cell lines. (PMID: 26775595)
• The strong association of the MST1R variant c.G917A:p.R306H with nasopharyngeal carcinoma. (PMID: 26951679)
• The role of nuclear RON in activating DNA repair under hypoxic conditions and conferring chemoresistance. (PMID: 26772202)
• Aberrant glycosylation of RON as a mechanism of oncogenic activation. (PMID: 26721331)
• The interplay between splicing factors and RON alternative splicing patterns in ovarian cancer. (PMID: 25997828)
• RON activation as an alternative mechanism in the development of castration-resistant prostate cancer (CRPC). (PMID: 26152593)
• The prognostic significance of MET and RON co-expression in early-stage disease. (PMID: 25874493)
• Elevated RON expression in endometrial adenocarcinoma compared to normal endometrial tissues. (PMID: 26189249)
• The role of DEK overexpression, driven partly by RON activation, in breast cancer progression through Wnt/beta-catenin signaling. (PMID: 24954505)
• The identification of MST1R (RON) among genes whose overexpression can compensate for EGFR in EGFR-dependent cells. (PMID: 25512530)
• The promotion of Ron proto-oncogene exon 11 inclusion by SRSF2. (PMID: 25220236)
• RON's function as a transcriptional regulator promoting cancer cell survival under hypoxia. (PMID: 24903148)
• The regulation of MET and RON by PAX8 in non-small cell lung cancer. (PMID: 24628993)
• The overexpression and activation of RON in pancreatic tumor specimens. (PMID: 24518495)
• The role of RON in laryngeal squamous cell carcinoma (SCC) invasion and migration. (PMID: 24287326)
• The contribution of RON to breast cancer metastasis through altered DNA methylation. (PMID: 24388747)
• The identification of dinucleotide sequences in exon 11 influencing RON pre-mRNA splicing. (PMID: 24189591)
• Intron retention in the RON gene. (PMID: 24155930)
• The Ron-c-Abl-PCNA pathway in oncogene-induced cell proliferation in breast cancer. (PMID: 23542172)
• MET and MST1R as independent prognostic factors in classical Hodgkin's lymphoma. (PMID: 23558571)
• The frequent expression of the RON160 isoform in breast cancer tissues. (PMID: 23597200)
• The prognostic significance of the MET(-) RON(-) phenotype in cancer. (PMID: 23745832)
• RON's role in mediating lapatinib resistance in breast cancer cells. (PMID: 23811285)
• The multidimensional role of RON in tumorigenesis, beyond simple oncogene or tumor suppressor classification. (PMID: 23483216)
• RON's involvement in carcinogenesis across various malignancies. (PMID: 23294341)
• The synergistic effect of RON and EGFR in head and neck squamous cell carcinomas. (PMID: 23799848)
• The lack of association between RON expression and prognosis or therapeutic response in resected pancreatic cancer. (PMID: 22958871)
• Cytoplasmic phosphorylated RON as a potential poor prognosis marker in esophageal squamous cell carcinoma. (PMID: 22086736)
• The identification of novel RON splice variants involving exons 5 and 6. (PMID: 22993024)
• The association of high RON expression with acute myeloid leukemia. (PMID: 22902361)
• The role of RON in nasopharyngeal carcinoma tumorigenesis and metastasis. (PMID: 22974584)
• The impact of RON knockdown on invasive growth and oncogenic signaling pathways in cancer. (PMID: 23235762)
• A new RON splice variant and its potential role in colorectal cancer metastasis. (PMID: 22975341)
• The structural determination of RON Sema-PSI domains. (PMID: 22848655)
• High RON expression in small and non-small cell lung cancers. (PMID: 22585712)
• Tumor promoter-induced RON expression via Egr-1 and its effects on cell invasiveness. (PMID: 22095683)
• The potential of elevated RON expression as a prognostic indicator in non-small cell lung cancer (NSCLC). (PMID: 22613539)

HGNC: 7381

OMIM: 255995

KEGG: hsa:4486

STRING: 9606.ENSP00000296474

UniGene: Hs.517973